Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1182/blood-2014-09-568899 http://scihub22266oqcxt.onion/10.1182/blood-2014-09-568899 C4432003!4432003 !25838344     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25838344 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Blood 2015 ; 125 (20 ): 3069-75 Nephropedia Template TP {{tp|p=25838344 |t=2015. Smoldering multiple myeloma |pdf=|usr=}}{{25838344 }} gab.com Text Smoldering multiple myeloma JO: Blood http://www.kidney.de/pget.php?&tw=1&pmid=25838344 #FOAvip Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. SMM is distinguished from monoclonal gammopathy of undetermined significance by a much higher risk of progression to multiple myeloma (MM). There have been major advances in the diagnosis, prognosis, and management of SMM in the last few years. These include a revised disease definition, identification of several new prognostic factors, a classification based on underlying cytogenetic changes, and new treatment options. Importantly, a subset of patients previously considered SMM is now reclassified as MM on the basis of biomarkers identifying patients with an ?80% risk of progression within 2 years. SMM has assumed greater significance on the basis of recent trials showing that early therapy can be potentially beneficial to patients. As a result, there is a need to accurately diagnose and risk-stratify patients with SMM, including routine incorporation of modern imaging and laboratory techniques. In this review, we outline current concepts in diagnosis and risk stratification of SMM, and provide specific recommendations on the management of SMM. Twit Text FOAVip Smoldering multiple myeloma ????Blood http://www.kidney.de/pget.php?&tw=1&pmid=25838344 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25838344 #FOAvip English Wikipedia <ref>{{Cite pmid|25838344 }}</ref> Smoldering multiple myeloma #MMPMID25838344 Rajkumar SV ; Landgren O ; Mateos MV Blood 2015[May]; 125 (20 ): 3069-75 PMID25838344 show ga Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. SMM is distinguished from monoclonal gammopathy of undetermined significance by a much higher risk of progression to multiple myeloma (MM). There have been major advances in the diagnosis, prognosis, and management of SMM in the last few years. These include a revised disease definition, identification of several new prognostic factors, a classification based on underlying cytogenetic changes, and new treatment options. Importantly, a subset of patients previously considered SMM is now reclassified as MM on the basis of biomarkers identifying patients with an ?80% risk of progression within 2 years. SMM has assumed greater significance on the basis of recent trials showing that early therapy can be potentially beneficial to patients. As a result, there is a need to accurately diagnose and risk-stratify patients with SMM, including routine incorporation of modern imaging and laboratory techniques. In this review, we outline current concepts in diagnosis and risk stratification of SMM, and provide specific recommendations on the management of SMM. |*Asymptomatic Diseases [MESH] |Clonal Evolution [MESH] |Disease Management [MESH] |Disease Progression [MESH] |Humans [MESH] |Multiple Myeloma/*diagnosis/etiology/therapy [MESH]Smoldering multiple myeloma (epmc).pdf DeepDyve Pubget Overpricing